Published in J Clin Invest on March 01, 2012
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest (2014) 0.97
Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game. Mediators Inflamm (2012) 0.94
A conserved domain in exon 2 coding for the human and murine ARF tumor suppressor protein is required for autophagy induction. Autophagy (2013) 0.87
Role of the tumor suppressor ARF in macrophage polarization: Enhancement of the M2 phenotype in ARF-deficient mice. Oncoimmunology (2012) 0.85
Significance of MMP11 and P14(ARF) expressions in clinical outcomes of patients with laryngeal cancer. Int J Clin Exp Med (2015) 0.84
Epigenetic mechanisms in oral carcinogenesis. Future Oncol (2012) 0.83
P14ARF suppresses tumor-induced thrombosis by regulating the tissue factor pathway. Cancer Res (2014) 0.81
TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status. DNA Cell Biol (2014) 0.78
Tumor suppressor ARF regulates tissue microenvironment and tumor growth through modulation of macrophage polarization. Oncotarget (2016) 0.75
Differential proteomics analysis of low- and high-grade of astrocytoma using iTRAQ quantification. Onco Targets Ther (2016) 0.75
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell (1997) 12.41
Matrix metalloproteinases: a review. Crit Rev Oral Biol Med (1993) 9.03
ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell (1998) 8.99
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33
Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell (1995) 7.34
Sp1 and krüppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol (2001) 5.81
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin (2010) 5.53
The role of angiogenesis in tumor growth. Semin Cancer Biol (1992) 5.33
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol (1999) 4.15
P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A (1999) 3.78
A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci (1996) 3.49
Distinct regions of Sp1 modulate DNA binding and transcriptional activation. Science (1988) 3.23
A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med (2003) 3.20
Tumor spectrum in ARF-deficient mice. Cancer Res (1999) 3.11
INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res (2005) 3.08
The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol (1997) 2.76
p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev (2000) 2.74
Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene (1997) 2.50
Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest (1991) 2.28
Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res (1999) 2.17
Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest (2004) 2.03
Sp-1 binds promoter elements regulated by the RB protein and Sp-1-mediated transcription is stimulated by RB coexpression. Proc Natl Acad Sci U S A (1993) 1.84
Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res (1998) 1.83
Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res (2000) 1.74
p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. Proc Natl Acad Sci U S A (1998) 1.73
Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev (2004) 1.71
A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet (2001) 1.70
Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res (2005) 1.67
Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet (1994) 1.66
Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene (2005) 1.61
HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem (2001) 1.60
Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res (2007) 1.56
Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene (2001) 1.55
Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene (2002) 1.52
p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. PLoS Biol (2004) 1.44
Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. Cancer Res (1999) 1.44
Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res (2009) 1.39
Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis. Oncogene (2002) 1.30
Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab Invest (2005) 1.29
Defining the molecular basis of Arf and Hdm2 interactions. J Mol Biol (2001) 1.29
Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J Biol Chem (1993) 1.27
Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res (2008) 1.24
MDM2: life without p53. Trends Genet (2001) 1.22
p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene (2003) 1.20
Oncogenic Ras induces p19ARF and growth arrest in mouse embryo fibroblasts lacking p21Cip1 and p27Kip1 without activating cyclin D-dependent kinases. J Biol Chem (2000) 1.20
p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene (2000) 1.20
p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. J Biol Chem (1995) 1.20
The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha ) and inhibits HIF-1-mediated transcription. J Biol Chem (2001) 1.17
Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing mouse eye. EMBO J (2005) 1.06
The INK4a/ARF locus in murine tumorigenesis. Carcinogenesis (2000) 1.04
Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration. J Invest Dermatol (1995) 1.02
Inhibition of colon tumor progression and angiogenesis by the Ink4a/Arf locus. Cancer Res (2003) 1.00
Identification of an initiator-like element essential for the expression of the tissue inhibitor of metalloproteinases-4 (Timp-4) gene. Biochem J (2002) 1.00
NF-Y and Sp1 cooperate for the transcriptional activation and cAMP response of human tissue inhibitor of metalloproteinases-2. J Biol Chem (2000) 0.99
p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners. Cell Cycle (2005) 0.98
Temporal and spatial regulation of gene expression mediated by the promoter for the human tissue inhibitor of metalloproteinases-3 (TIMP-3)-encoding gene. Dev Dyn (1998) 0.95
ARF suppresses tumor angiogenesis through translational control of VEGFA mRNA. Cancer Res (2010) 0.93
Regulation of MyoD activity and muscle cell differentiation by MDM2, pRb, and Sp1. J Biol Chem (2003) 0.92
Structure of the human TIMP-3 gene and its cell cycle-regulated promoter. Biochem J (1995) 0.92
pRB induces Sp1 activity by relieving inhibition mediated by MDM2. Proc Natl Acad Sci U S A (2001) 0.89
Sp1-dependent regulation of the tissue inhibitor of metalloproteinases-1 promoter. J Cell Biochem (2004) 0.89
Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways. Oncogene (2002) 0.87
Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. Clin Cancer Res (2003) 0.85
Glioma-stimulated chemoattraction of endothelial cells and fibroblasts in vitro: a model for the study of glioma-induced angiogenesis. Metab Brain Dis (1994) 0.82
The transforming activities of MDM2 in cultured neonatal rat astrocytes. Oncogene (1996) 0.80
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Natural mutagenesis of human genomes by endogenous retrotransposons. Cell (2010) 5.50
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
An integrative approach for in silico glioma research. IEEE Trans Biomed Eng (2010) 4.55
Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem (2002) 4.17
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med (2007) 4.11
CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal (2009) 3.77
The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol (2005) 3.42
CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. J Clin Invest (2008) 3.29
A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem (2002) 3.17
A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab (2006) 3.06
Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res (2004) 2.90
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res (2008) 2.81
CD36 involvement in orosensory detection of dietary lipids, spontaneous fat preference, and digestive secretions. J Clin Invest (2005) 2.81
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res (2004) 2.79
Discovery of a proneurogenic, neuroprotective chemical. Cell (2010) 2.78
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol (2005) 2.74
Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol (2004) 2.71
Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc Natl Acad Sci U S A (2005) 2.71
Integrated morphologic analysis for the identification and characterization of disease subtypes. J Am Med Inform Assoc (2012) 2.68
Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J Exp Med (2006) 2.51
CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov (2012) 2.51
Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest (2004) 2.45
Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology (2007) 2.43
Real-time magnetic resonance-guided stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy. Neurosurgery (2014) 2.41
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol (2011) 2.39
'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol (2006) 2.37
CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res (2007) 2.31
Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes (2007) 2.24
Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Am J Clin Pathol (2005) 2.17
Pituicytoma: report of two cases and clues regarding histogenesis. Neurosurgery (2004) 2.17
A CD36-dependent pathway enhances macrophage and adipose tissue inflammation and impairs insulin signalling. Cardiovasc Res (2010) 2.16
Reactive retinal astrocytic tumors (so-called vasoproliferative tumors): histopathologic, immunohistochemical, and genetic studies of four cases. Am J Ophthalmol (2012) 2.12
Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest (2004) 2.03
The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One (2010) 1.86
The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J Neurosci (2005) 1.84
Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia (2002) 1.81
Vav guanine nucleotide exchange factors link hyperlipidemia and a prothrombotic state. Blood (2011) 1.79
Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II. Cardiovasc Res (2007) 1.78
Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest (2008) 1.77
MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology (2013) 1.77
The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice. Proc Natl Acad Sci U S A (2005) 1.71
Cancer susceptibility variants and the risk of adult glioma in a US case-control study. J Neurooncol (2011) 1.69
Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res (2005) 1.67
A specific CD36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein. Circ Res (2008) 1.66
Integrative, multimodal analysis of glioblastoma using TCGA molecular data, pathology images, and clinical outcomes. IEEE Trans Biomed Eng (2011) 1.63
Macrophage gene expression and foam cell formation are regulated by plasminogen. Circulation (2013) 1.63
Machine-based morphologic analysis of glioblastoma using whole-slide pathology images uncovers clinically relevant molecular correlates. PLoS One (2013) 1.62
Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res (2002) 1.62
TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell Immunol (2009) 1.61
Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene (2005) 1.61
Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol (2004) 1.61
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 1.60
The role of the scavenger receptor CD36 in regulating mononuclear phagocyte trafficking to atherosclerotic lesions and vascular inflammation. Cardiovasc Res (2009) 1.59
Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am J Pathol (2004) 1.58
Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. Gene (2002) 1.58
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. J Lipid Res (2003) 1.54
CD36-mediated cholesterol efflux is associated with PPARgamma activation via a MAPK-dependent COX-2 pathway in macrophages. Cardiovasc Res (2009) 1.54
Requirements for apoptotic cell contact in regulation of macrophage responses. J Immunol (2006) 1.53
Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs (2005) 1.52
Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene (2002) 1.52
PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion. J Biol Chem (2004) 1.47
Astroblastoma: radiologic-pathologic correlation and distinction from ependymoma. AJNR Am J Neuroradiol (2002) 1.44
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
CD36 participates in a signaling pathway that regulates ROS formation in murine VSMCs. J Clin Invest (2010) 1.41
Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology (2012) 1.41
The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Natl Acad Sci U S A (2003) 1.40
IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst (2010) 1.39
Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res (2009) 1.39
Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes. Exp Neurol (2004) 1.36
Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res (2003) 1.36
CD36 mediates the phagocytosis of Plasmodium falciparum-infected erythrocytes by rodent macrophages. J Infect Dis (2004) 1.36
CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride clearance. J Lipid Res (2005) 1.35
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis. J Lipid Res (2007) 1.34
Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology (2010) 1.33
Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res (2009) 1.33
Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res (2004) 1.32
Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms. Blood (2011) 1.32
A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. Gastroenterology (2010) 1.31
A null mutation in skeletal muscle FAT/CD36 reveals its essential role in insulin- and AICAR-stimulated fatty acid metabolism. Am J Physiol Endocrinol Metab (2007) 1.29
Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol (2002) 1.29
PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res (2005) 1.28